We present a physiological pharmacokinetic model that describes the pl
asma and cerebrospinal fluid (CSF) concentrations of topotecan [(S)-9-
dimethylaminomethyl-10-hydroxycamptothecin hydrochloride, SKandF 10486
3-A, NSC 609699] following i.v. and intraventricular administrations i
n monkeys. The model consists of three physical spaces: the CSF, the p
lasma, and a body compartment. The model incorporates such processes a
s reversible conversion of topotecan lactone to an inactive hydroxy ac
id form, microvascular exchange between CSF and plasma, bulk CSF flow,
exchange between plasma and body compartments, and elimination of dru
g from the plasma compartment. Several parameters in the model mere ob
tained from published literature on the physiology of the monkey. The
model mas then fit to the plasma and CSF data to deduce the other para
meters. Calculated clearances of topotecan lactone and total drug from
the CSF after intraventricular injection mere 3.9 and 2.2 ml/h, respe
ctively. Clearances of topotecan lactone and total drug from the plasm
a following a 10-min infusion were 26.3 liters/h/m(2) and 17.8 liters/
h/m(2), respectively. The calculated ratios of the area under the conc
entration curve in the CSP following i.v. infusion to the area under t
he concentration curve in plasma mere 0.11 and 0.19 for topotecan and
total drug, respectively, indicating significant CSF penetration. The
volume of distribution was 0.77 liters/kg, which represents distributi
on in a volume approximating total body mater. The forward and reverse
rate constants for the lactone-to-hydroxy acid conversion mere 1.0 an
d 0.29 h(-1), respectively. Comparison of the clearances (normalized t
o body surface area) with values reported for mice and humans shows re
asonable similarity across species. This pharmacokinetic model may hel
p guide future development and refinement of clinical protocols, espec
ially in the treatment of diseases of the central nervous system.